23/10/2019 US Defence Grant to Study Imugene CF33 Oncolytic Virotherapy

21/10/2019 CF33 Oncolytic Virus Clinical Trial Program Update

17/10/2019 Imugene appoints Professor Yuman Fong, MD, of City of Hope to Chair Oncolytic Virotherapy Scientific Advisory Board

14/10/2019 Notice of Extraordinary General Meeting/Proxy Form

09/10/2019 Notice of UMP Facility to Eligible Shareholders

04/10/2019 Share Sale Facility for Holders of Unmarketable Parcels

04/10/2019 Notice of Annual General Meeting/Proxy Form

01/10/2019 Imugene Cancer Vaccine Combinations Presented at ESMO

01/10/2019 Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO

26/07/2019 ! Appendix 4C - quarterly

26/07/2019 2019 Bioshares Presentation

15/07/2019 Imugene Enhances Portfolio with Compelling Oncolytic Virus

08/07/2019 New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer

04/06/2019 Updated Phase Ib HER-Vaxx data presented at the American Society of Clinical Oncology 2019 Annual Meeting

20/05/2019 Global Biotechnology and Venture Capital Executive Joins Imugene Board

01/05/2019 Investor Presentation

29/04/2019 New Cancer Vaccine Trial Data presented at ASCO 2019

24/04/2019 Leading Global Pharmaceutical Executive Joins Imugene Board

16/04/2019 Investor Presentation

03/04/2019 Medical University Vienna presents positive new data on one of Imugene’s lead PD-1 mimotope cancer vaccines at the American Association for Cancer Research 2019 Annual Meeting

02/04/2019 New Data on Imugene’s Lead PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines presented at the American Association for Cancer Research 2019 Annual Meeting

02/04/2019 Positive New Data on Imugene’s HER-Vaxx Cancer Vaccine Phase Ib trial presented at the American Association for Cancer Research 2019 Annual Meeting

26/03/2019 Investor Presentation

20/03/2019 Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

14/03/2019 Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

04/03/2019 Imugene Announces Presentations on Lead PD-1 and HER-2 Cancer Vaccines at the American Association for Cancer Research 2019 Annual Meeting

28/02/2019 Half Yearly Report and Accounts

28/02/2019 Pause in Trading

28/02/2019 Imugene Announces Presentation on HER-Vaxx Cancer Vaccine at the American Association for Cancer Research 2019 Annual Meeting

26/02/2019 Prestigious Clinical Cancer Research Journal Publishes B-Vaxx Phase 1 Data

07/01/2019 Imugene appoints distinguished scientist, Dr Michael Caligiuri of City of Hope to Scientific Advisory Board


17/12/2018 Imugene Meets Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

13/11/2018 Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial

09/11/2018 Imugene Receives $1.85 million R&D Tax Incentive

04/10/2018 European Society for Medical Oncology President joins Imugene Scientific Advisory Board

01/10/2018 Imugene appoints leading cancer researcher to Scientific Advisory Board

21/09/2018 Imugene commences cGMP manufacture of PD-1 cancer vaccine

18/09/2018 Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board

11/09/2018 Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

23/08/2018 Imugene appoints Dr Mark Marino Chief Medical Officer 

27/07/2018 2018 Bioshares Presentation

23/07/2018 PD-1 cancer vaccine development update

07/06/2018 Capital Raising Presentation

07/06/2018 Prospectus

07/06/2018 Imugene to Raise A$20.1 million

07/06/2018 Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio

05/06/2018 Trading Halt

28/03/2018 Leslie Chong Appointed as Managing Director

18/02/2018 Imugene arginine modulator demonstrates activity in melanoma cancer model

11/02/2018 Novel Anti-PD-1 Mimotope Vaccine Ready for Development

09/02/2018 Imugene hosts investigator meeting for gastric cancer clinical trial

07/02/2018 Cancer vaccine shows early promise in gastric cancer clinical trial

29/01/2018 Business Update – December Quarter Appendix 4C


04/12/2017 International Cancer Specialist Joins Imugene’s SAB


23/11/2017 IMU - Prospectus

23/11/2017 IMU Capital Raising Presentation

23/11/2017 Entitlement Offer - notice to option holders

23/11/2017 Entitlement Offer - notice to ineligible shareholders

23/11/2017 Entitlement Offer – notice to eligible shareholders

24/10/2017 Imugene Limited to Present at Australia Biotech Invest 2017

16/10/2017 Expert briefing and Q&A

11/10/2017 Imugene Receives $1.1 million in Research and Development Tax Refund

06/10/2017 Imugene Investor Presentation

31/08/2017 Imugene commences first patient dosing of HER-Vaxx

21/07/2017 Canadian patent granted for HER-Vaxx

17/07/2017 Investor Presentation July 2017

26/06/2017 Change of Address

30/03/2017 $1.35 million Options Underwritten

27/02/2017 Intellectual Property Strengthened Around Lead Clinical Drug HER-Vaxx

13/02/2017 Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research

09/01/2017 Presentation by Leslie Chong at 9th Annual Biotech Showcase, San Francisco 9 Jan 17